RT Journal Article
SR Electronic
T1 Therapeutic effects of human amnion-derived mesenchymal stem cells on hypercoagulability in a uremic calciphylaxis patient
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.06.22283161
DO 10.1101/2023.01.06.22283161
A1 Bian, Anning
A1 Ye, Xiaoxue
A1 Wang, Jing
A1 Zeng, Ming
A1 Liu, Jiayin
A1 Liu, Kang
A1 Ning, Song
A1 Cui, Yugui
A1 Tang, Shaowen
A1 Xu, Xueqiang
A1 Yuan, Yanggang
A1 Su, Zhonglan
A1 Lu, Yan
A1 Zhou, Jing
A1 Ma, Xiang
A1 Yang, Guang
A1 Huang, Yaoyu
A1 Lv, Xiaolin
A1 Wang, Ling
A1 Zhao, Jing
A1 Wang, Xiuqin
A1 Liang, Ningxia
A1 Xing, Changying
A1 Qin, Lianju
A1 Wang, Ningning
YR 2023
UL http://medrxiv.org/content/early/2023/01/07/2023.01.06.22283161.abstract
AB Calciphylaxis is a rare cutaneous vascular disease with clinical manifestations of intolerable pains, non-healing skin wounds, histologically characterized by calcification, fibrointimal hyperplasia, and thrombosis in microvessels. Currently, there are no approved guidelines for this disease. High prevalence of thrombophilias and hypercoagulable conditions in calciphylaxis patients have been recognized in recent years. Here, we report a case of uremic calciphylaxis patient whom was refractory to conventional treatments and then received a salvage strategy via human amnion-derived mesenchymal stem cell (hAMSC) intravenous combined with local application. In order to investigate the therapeutic mechanism of hMASCs from the novel perspective of hypercoagulability, coagulation-related indicators, wound status and quality of life were followed up. Improvement of hypercoagulable condition involving correction of platelet, D-dimer and plasminogen levels, skin regeneration and pain alleviation were revealed after hAMSC administration for one year. We propose that hypercoagulability is the therapeutic target of calciphylaxis patients which can be improved by hAMSC treatment.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04592640Funding StatementThis study was funded by the National Natural Science Foundation of China (81270408, 81570666, 81730041, and 81671447), the International Society of Nephrology (ISN) Clinical Research Program (18-01-0247), Construction Program of Jiangsu Provincial Clinical Research Center Support System (BL2014084), Jiangsu Province Key Medical Personnel Project (ZDRCA2016002), CKD Anemia Research Foundation from China International Medical Foundation (Z-2017-24-2037), Outstanding Young and Middle-Aged Talents Support Program of The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), the National Key Research and Development Program of China (2017YFC1001303), the Program of Jiangsu Province Clinical Medical Center (YXZXB2016001, BL2012009), the State Key Laboratory of Reproductive Medicine Program (SKLRM-GC201803), and the Program of Jiangsu Commission of Health (H201605).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Jiangsu Province Hospital (2012-SR-128, 2018-QT-001) gave ethical approval for this work. Healthy pregnant women in their 20s or 30s who provided written informed consent donated human amniotic membranes, which was approved by the Ethics Committee of Jiangsu Province Hospital (2012-SR-128).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.hAMSChuman amnion-derived mesenchymal stem cellCUAcalcific uremic arteriolopathyESKDend-stage kidney diseasePDperitoneal dialysisSHPTsecondary hyperparathyroidismVASVisual Analog ScaleBWATBates-Jensen Wound AssessmentWound-QoLWound-Quality of LifeCKRTcontinuous kidney replacement therapyCRPC reactive proteinTFtissue factorPRPplatelet-rich plasma.